The US Food and Drug Administration approved changes on October 30 to boxed warnings on three estradiol patches used for menopause symptoms, HHS announced. Statements on cardiovascular disease, breast cancer and probable dementia will leave the most prominent warning section. The action comes amid rising demand and difficulty obtaining treatment.
The decision extends changes approved for six hormone therapies in February. HHS said a review of scientific literature supported the revisions; 29 companies have submitted proposed label changes since the initiative began in November 2025. The Guardian reported that researchers questioned the decision’s transparency and potential to understate harms.
Reuters reported that women have struggled to obtain estrogen patches for symptoms including hot flashes, mood swings and disrupted sleep. The agency has worked with manufacturers since September to increase supply, but has not formally classified the patches as being in shortage. HHS acknowledged local access problems while reporting no known imminent nationwide shortage risk.
Officials told Reuters that patch output doubled over the past year. FDA official Sarah Ibrahim said the agency expedited approval of 10 manufacturing changes this year that could expand production, including two in the past week. Manufacturers are adding capacity and shifts, according to HHS.
The FDA’s February announcement advised women to consult product labels and health professionals about benefits and risks. Hormone therapies have approvals for uses including moderate-to-severe hot flashes, vaginal discomfort and prevention of bone loss. The latest action changes safety labeling for three products; it does not establish that every patient should receive hormone treatment.
HHS said the FDA is also exploring nonprescription vaginal estrogen with companies. Any such switch still needs approval and evidence of safe, effective use without professional supervision. For patients unable to obtain their usual patches, the department advised discussing suitable alternatives with a pharmacist or healthcare provider.
Comments